What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles .”In the company’s words, NCT06238843 on ClinicalTrials.gov
- Tested for
- Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer, CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Locally Advanced Unresectable or Metastatic Solid Tumors
- Main trialPhase 3
- “This is a Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects with Previously Treated Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma to compare the progression free survival (PFS) and overall survival (OS)”In the company’s words, NCT06238843 on ClinicalTrials.gov
- Other names
- Arcotatug Tavatecan
Other drugs for Pancreatic Cancer
- CAM2029Camurus AB · Phase 3
- Immuncell-LCGC Cell Corporation · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- XNW28012Evopoint Biosciences Inc. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- DaraxonrasibRevolution Medicines · Phase 3
Coming up4
- 30 DecPhase 3 trial completes · ClinicalTrials.gov
- 30 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Jun 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 Mar 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Dec 2026 | A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001) | |
| Phase 3Recruiting | 30 Jun 2027 | A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002) | |
| Phase 2Recruiting | 31 Mar 2028 | IBI343 in Combination Therapy for Advanced Malignant Solid Tumors | |
| Phase 1Recruiting | 30 Jun 2027 | A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026